Teva Pharmaceutical Industries Ltd. $TEVA Stake Lifted by Altshuler Shaham Ltd

Altshuler Shaham Ltd raised its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.4% during the fourth quarter, Holdings Channel reports. The fund owned 8,494,121 shares of the company’s stock after buying an additional 196,697 shares during the period. Teva Pharmaceutical Industries makes up approximately 3.9% of Altshuler Shaham Ltd’s portfolio, making the stock its 6th largest position. Altshuler Shaham Ltd’s holdings in Teva Pharmaceutical Industries were worth $268,670,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $255,000. Flow Traders U.S. LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $238,000. Finally, Cerity Partners LLC lifted its stake in shares of Teva Pharmaceutical Industries by 2.9% during the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after buying an additional 1,291 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TEVA. Piper Sandler restated an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 21,258 shares of the stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total value of $750,619.98. Following the transaction, the executive vice president owned 63,647 shares of the company’s stock, valued at $2,247,375.57. This represents a 25.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Richard Daniell sold 30,000 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. The trade was a 34.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 465,931 shares of company stock worth $16,332,989. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $32.59 on Thursday. The firm’s 50 day simple moving average is $33.46 and its 200 day simple moving average is $32.17. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $37.47 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 3.36 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.